SHARE THIS VIDEO —
Maker of popular diabetes and weight-loss drugs grilled about high cost in the U.S.
NBC News Clone summarizes the latest on: Mmvo220062277988 - Breaking News | NBC News Clone. This article is rewritten and presented in a simplified tone for a better reader experience.
The CEO of Novo Nordisk was questioned about the high cost in the U.S. of Wegovy and Ozempic, the wildly popular diabetes and weight-loss drugs. Lars Jorgensen said pharmacy benefit managers are mostly to blame. NBC News' Stephanie Gosk reports.
Stay informed with daily digest and insights from NBC News Clone. We repackage top headlines for our global readers.
